Literature DB >> 12736472

Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension.

Fumiaki Ono1, Noritoshi Nagaya, Shingo Kyotani, Hideo Oya, Norifumi Nakanishi, Kunio Miyatake.   

Abstract

Earlier studies have shown that administration of beraprost sodium (BPS), an orally active prostacyclin analogue, improves hemodynamics in patients with primary pulmonary hypertension (PH), but it is not known whether BPS has beneficial effects in secondary precapillary PH. The present study investigated the hemodynamic and hormonal parameters of 18 patients with secondary precapillary PH (8 patients with chronic thromboembolic PH, 7 with collagen vascular disease, and 3 with residual PH after surgery for atrial septal defect). Hemodynamics were repeatedly measured by right heart catheterization. Treatment with BPS improved New York Heart Association (NYHA) functional class in 10 of the 18 patients and significantly decreased pulmonary vascular resistance by 17% (12.9+/-1.1 to 10.7+/-1.2 Wood units, p<0.01). Circulating brain natriuretic peptide and uric acid significantly decreased from 246+/-61 to 215+/-65 pg/ml and from 6.5+/-0.6 to 5.3+/-0.3 mg/dl, respectively. In summary, BPS therapy improved NYHA functional class, hemodynamics, and hormonal parameters in patients with secondary precapillary PH. Thus, oral administration of BPS may be a new therapeutic strategy for the treatment of secondary precapillary PH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12736472     DOI: 10.1253/circj.67.375

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease.

Authors:  A Limsuwan; P Pienvichit; P Khowsathit
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

Review 2.  Drug treatment of pulmonary hypertension in children.

Authors:  Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

Review 3.  Prostacyclin for pulmonary hypertension in adults.

Authors:  N S Paramothayan; T J Lasserson; A U Wells; E H Walters
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

4.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

Review 5.  Drug Treatment of Pulmonary Hypertension in Children.

Authors:  Catherine M Avitabile; Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.